Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021

被引：12
作者：
Cui, Xiaoni [1 ]
Wang, Pengxiang [1 ]
Wei, Zhun [2 ,3 ]
机构：
[1] Sino Cell Biomed Co Ltd, Qingdao, Shandong, Peoples R China
[2] Qingdao Univ, Sch Pharm, Inst Innovat Drugs, Qingdao 266003, Shandong, Peoples R China
[3] Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao 266003, Shandong, Peoples R China
来源：
DRUG DISCOVERIES AND THERAPEUTICS | 2021年 / 15卷 / 04期
关键词：
COVID-19; vaccine research; mRNA; adenoviral vectors; inactivated viruses; recombinant proteins; BNT162B2;
D O I：
10.5582/ddt.2021.01064
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 (COVID-19), and the resulting pandemic has caused widespread health problems and social and economic disruption. Thus far in 2021, more than 4 million people worldwide have died from COVID-19, so safe and efficacious vaccines are urgently needed to restore normal economic and social activities. According to the official guidance documents of the World Health Organization (WHO), vaccines based on four major strategies including mRNA, adenoviral vectors, inactivated viruses, and recombinant proteins have entered the stage of emergency use authorization and pre-certification evaluation. The current review summarizes these vaccines and it looks ahead to the development of additional COVID-19 vaccines in the future.
引用
收藏
页码：222 / 224
页数：3
相关论文
共 22 条
  • [1] Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration
    AboulFotouh, Khaled
    Cui, Zhengrong
    Williams, Robert O., III
    [J]. AAPS PHARMSCITECH, 2021, 22 (03)
  • [2] Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
    Al Kaabi, Nawal
    Zhang, Yuntao
    Xia, Shengli
    Yang, Yunkai
    Al Qahtani, Manaf M.
    Abdulrazzaq, Najiba
    Al Nusair, Majed
    Hassany, Mohamed
    Jawad, Jaleela S.
    Abdalla, Jehad
    Hussein, Salah Eldin
    Al Mazrouei, Shamma K.
    Al Karam, Maysoon
    Li, Xinguo
    Yang, Xuqin
    Wang, Wei
    Lai, Bonan
    Chen, Wei
    Huang, Shihe
    Wang, Qian
    Yang, Tian
    Liu, Yang
    Ma, Rui
    Hussain, Zaidoon M.
    Khan, Tehmina
    Saifuddin Fasihuddin, Mohammed
    You, Wangyang
    Xie, Zhiqiang
    Zhao, Yuxiu
    Jiang, Zhiwei
    Zhao, Guoqing
    Zhang, Yanbo
    Mahmoud, Sally
    ElTantawy, Islam
    Xiao, Peng
    Koshy, Ashish
    Zaher, Walid Abbas
    Wang, Hui
    Duan, Kai
    Pan, An
    Yang, Xiaoming
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01): : 35 - 45
  • [3] [Anonymous], Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process
  • [4] Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
    Bernal, Jamie Lopez
    Andrews, Nick
    Gower, Charlotte
    Robertson, Chris
    Stowe, Julia
    Tessier, Elise
    Simmons, Ruth
    Cottrell, Simon
    Roberts, Richard
    O'Doherty, Mark
    Brown, Kevin
    Cameron, Claire
    Stockton, Diane
    McMenamin, Jim
    Ramsay, Mary
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [5] Emerging Concepts and Technologies in Vaccine Development
    Brisse, Morgan
    Vrba, Sophia M.
    Kirk, Natalie
    Liang, Yuying
    Ly, Hinh
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [6] Viral targets for vaccines against COVID-19
    Dai, Lianpan
    Gao, George F.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2021, 21 (02) : 73 - 82
  • [7] Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
    Haas, Eric J.
    Angulo, Frederick J.
    McLaughlin, John M.
    Anis, Emilia
    Singer, Shepherd R.
    Khan, Farid
    Brooks, Nati
    Smaja, Meir
    Mircus, Gabriel
    Pan, Kaijie
    Southern, Jo
    Swerdlow, David L.
    Jodar, Luis
    Levy, Yeheskel
    Alroy-Preis, Sharon
    [J]. LANCET, 2021, 397 (10287) : 1819 - 1829
  • [8] SARS-CoV-2 virus: Vaccines in development
    Huang, Qingrui
    Yan, Jinghua
    [J]. FUNDAMENTAL RESEARCH, 2021, 1 (02): : 131 - 138
  • [9] Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
    Kandeil, Ahmed
    Mostafa, Ahmed
    Hegazy, Rehab R.
    El-Shesheny, Rabeh
    El Taweel, Ahmed
    Gomaa, Mokhtar R.
    Shehata, Mahmoud
    Elbaset, Marawan A.
    Kayed, Ahmed E.
    Mahmoud, Sara H.
    Moatasim, Yassmin
    Kutkat, Omnia
    Yassen, Noha N.
    Shabana, Marwa E.
    GabAllah, Mohamed
    Kamel, Mina Nabil
    Abo Shama, Noura M.
    El Sayes, Mohamed
    Ahmed, Amira N.
    Elalfy, Zahraa S.
    Mohamed, Bassim M. S. A.
    Abd El-Fattah, Safa N.
    El Hariri, Hazem Mohamed
    Abdel Kader, Mona
    Azmy, Osama
    Kayali, Ghazi
    Ali, Mohamed A.
    [J]. VACCINES, 2021, 9 (03) : 1 - 15
  • [10] Kifle ZD, 2021, J EVID-BASED INTEGR, V26, P1
123